Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma.

Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, Huang LX, He J, Zhao JJ, Jiang SS, Zhang XF, Zhang HX, Zhou ZQ, Weng de S, Xia JC.

Oncotarget. 2016 Mar 29;7(13):16248-61. doi: 10.18632/oncotarget.7637.

2.

A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.

Amaravadi RK, Schilder RJ, Martin LP, Levin M, Graham MA, Weng DE, Adjei AA.

Mol Cancer Ther. 2015 Nov;14(11):2569-75. doi: 10.1158/1535-7163.MCT-15-0475. Epub 2015 Sep 2.

3.

An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.

Morrow PK, Murthy RK, Ensor JD, Gordon GS, Margolin KA, Elias AD, Urba WJ, Weng DE, Rugo HS, Hortobagyi GN.

Cancer. 2012 Sep 1;118(17):4098-104. doi: 10.1002/cncr.26730. Epub 2012 Jan 26.

4.

The 2003 revised TNM staging system for breast cancer: results of stage re-classification on survival and future comparisons among stage groups.

Escobar PF, Patrick RJ, Rybicki LA, Weng DE, Crowe JP.

Ann Surg Oncol. 2007 Jan;14(1):143-7. Epub 2006 Oct 22.

PMID:
17058125
5.

Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.

Escobar PF, Patrick RJ, Rybicki LA, Hicks D, Weng DE, Crowe JP.

Ann Surg Oncol. 2006 Jun;13(6):783-7. Epub 2006 Apr 12.

PMID:
16604475
6.

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.

Weng DE, Masci PA, Radka SF, Jackson TE, Weiss PA, Ganapathi R, Elson PJ, Capra WB, Parker VP, Lockridge JA, Cowens JW, Usman N, Borden EC.

Mol Cancer Ther. 2005 Jun;4(6):948-55.

7.

Angiozyme: a novel angiogenesis inhibitor.

Weng DE, Usman N.

Curr Oncol Rep. 2001 Mar;3(2):141-6. Review.

PMID:
11177746
8.

Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.

Peng L, Kjaergaard J, Plautz GE, Weng DE, Shu S, Cohen PA.

J Immunol. 2000 Nov 15;165(10):5738-49.

9.

Detection of circulating tumor cells and micrometastases in stage II, III, and IV breast cancer patients utilizing cytology and immunocytochemistry.

Fetsch PA, Cowan KH, Weng DE, Freifield A, Filie AC, Abati A.

Diagn Cytopathol. 2000 May;22(5):323-8.

PMID:
10790242
10.

CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection.

Cohen PA, Peng L, Plautz GE, Kim JA, Weng DE, Shu S.

Crit Rev Immunol. 2000;20(1):17-56. Review.

PMID:
10770269
11.

Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents.

Koski GK, Schwartz GN, Weng DE, Gress RE, Engels FH, Tsokos M, Czerniecki BJ, Cohen PA.

Blood. 1999 Aug 15;94(4):1359-71.

PMID:
10438724
12.

Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways.

Koski GK, Schwartz GN, Weng DE, Czerniecki BJ, Carter C, Gress RE, Cohen PA.

J Immunol. 1999 Jul 1;163(1):82-92.

13.

Successful medical management of isolated renal zygomycosis: case report and review.

Weng DE, Wilson WH, Little R, Walsh TJ.

Clin Infect Dis. 1998 Mar;26(3):601-5. Review.

PMID:
9524830
14.

Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells.

Czerniecki BJ, Carter C, Rivoltini L, Koski GK, Kim HI, Weng DE, Roros JG, Hijazi YM, Xu S, Rosenberg SA, Cohen PA.

J Immunol. 1997 Oct 15;159(8):3823-37.

PMID:
9378970
15.

Differential gene expression in fetal mouse germ cells.

Urven LE, Weng DE, Schumaker AL, Gearhart JD, McCarrey JR.

Biol Reprod. 1993 Mar;48(3):564-74.

PMID:
8452933
16.

Loss of expression of the uvomorulin gene in compaction-defective embryonal carcinoma cells.

Weng DE, Littlefield JW.

Somat Cell Mol Genet. 1991 Nov;17(6):617-9.

PMID:
1767339
17.

Estimates of mRNA abundance in the mouse blastocyst based on cDNA library analysis.

Weng DE, Morgan RA, Gearhart JD.

Mol Reprod Dev. 1989;1(4):233-41.

PMID:
2483515
18.

Supplemental Content

Loading ...
Support Center